Potent and selective α-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase

被引:72
作者
Romero, F. Anthony
Du, Wu
Hwang, Inkyu
Rayl, Thomas J.
Kimball, F. Scott
Leung, Donmienne
Hoover, Heather S.
Apodaca, Richard L.
Breitenbucher, J. Guy
Cravatt, Benjamin F.
Boger, Dale L.
机构
[1] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
[4] Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA
关键词
D O I
10.1021/jm0611509
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A study of the structure-activity relationships (SAR) of 2f (OL-135), a potent inhibitor of fatty acid amide hydrolase (FAAH), is detailed, targeting the 5-position of the oxazole. Examination of a series of substituted benzene derivatives (12-14) revealed that the optimal position for substitution was the meta-position with selected members approaching or exceeding the potency of 2f. Concurrent with these studies, the effect of substitution on the pyridine ring of 2f was also examined. A series of small, nonaromatic C5-substituents was also explored and revealed that the K-i follows a well-defined correlation with the Hammett sigma(p) constant (rho = 3.01, R-2 = 0.91) in which electron-withdrawing substituents enhance potency, leading to inhibitors with K(i)s as low as 400 pM (20n). Proteomic-wide screening of the inhibitors revealed that most are exquisitely selective for FAAH over all other mammalian proteases, reversing the 100-fold preference of 20a (C5 substituent = H) for the enzyme TGH.
引用
收藏
页码:1058 / 1068
页数:11
相关论文
共 69 条
  • [1] Mechanism of carbamate inactivation of FAAH: Implications for the design of covalent inhibitors and in vivo functional probes for enzymes
    Alexander, JP
    Cravatt, BF
    [J]. CHEMISTRY & BIOLOGY, 2005, 12 (11): : 1179 - 1187
  • [2] Cannabinoid receptors and their endogenous agonist, anandamide
    Axelrod, J
    Felder, CC
    [J]. NEUROCHEMICAL RESEARCH, 1998, 23 (05) : 575 - 581
  • [3] Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide
    Boger, DL
    Sato, H
    Lerner, AE
    Hedrick, MP
    Fecik, RA
    Miyauchi, H
    Wilkie, GD
    Austin, BJ
    Patricelli, MP
    Cravatt, BF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) : 5044 - 5049
  • [4] Fatty acid amide hydrolase substrate specificity
    Boger, DL
    Fecik, RA
    Patterson, JE
    Miyauchi, H
    Patricelli, MP
    Cravatt, BF
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (23) : 2613 - 2616
  • [5] Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide
    Boger, DL
    Patterson, JE
    Guan, XJ
    Cravatt, BF
    Lerner, RA
    Gilula, NB
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) : 4810 - 4815
  • [6] Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide
    Boger, DL
    Patterson, JE
    Jin, Q
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) : 4102 - 4107
  • [7] Discovery of a potent, selective, and efficacious class of reversible α-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics
    Boger, DL
    Miyauchi, H
    Du, W
    Hardouin, C
    Fecik, RA
    Cheng, H
    Hwang, I
    Hedrick, MP
    Leung, D
    Acevedo, O
    Guimaraes, CRW
    Jorgensen, WL
    Cravatt, BF
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) : 1849 - 1856
  • [8] Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: A probe of structural and conformational features contributing to inhibition
    Boger, DL
    Sato, H
    Lerner, AE
    Austin, BJ
    Patterson, JE
    Patricelli, MP
    Cravatt, BF
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (02) : 265 - 270
  • [9] Boger DL, 1998, CURR PHARM DESIGN, V4, P303
  • [10] Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling
    Bracey, MH
    Hanson, MA
    Masuda, KR
    Stevens, RC
    Cravatt, BF
    [J]. SCIENCE, 2002, 298 (5599) : 1793 - 1796